ClinicalTrials.gg
RecruitingNCT06104033DCB-MVDUpdated Oct 27, 2023

Practice Change With Drug-coated Balloon in Patients With multiVessel Coronary Artery Disease

An observational study in Coronary Artery Disease and Multi Vessel Coronary Artery Disease, sponsored by Bon-Kwon Koo. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years to 100 Years. Per ClinicalTrials.gov, last updated 2023-10-27.

Sponsored by Bon-Kwon Koo · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 2 months ago, but the record still lists the study as recruiting.
  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
19 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 361 studies in Coronary Artery Disease with a site in Korea, Republic of — 81 open to participants now, 103 under way, 2 of them phase 3. Coronary Artery Disease · Korea, Republic of.

Planned enrollment
101st of 152
500 · median 1,113
Started
2023
with 23 others
Observational
153 of 361
40 open now
Primary completion
2025-08
later than 17 of 102 live
Registered
312th of 361
by date

Among the 361 studies in Coronary Artery Disease with a site in Korea, Republic of, this one is the 101st largest by planned enrollment of the 152 observational ones that give a count, is one of 24 that started in 2023, is one of 153 observational ones, reaches primary completion later than 17 of the 102 other live ones, and was the 312th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

81 of the 361 studies in Coronary Artery Disease with a site in Korea, Republic of are open now. Recruiting first, the newest first:

76 more — sign in →

All 81 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 19 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 361 studies in Coronary Artery Disease with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This study is a prospective, multicenter, open-label, observational study to investigate the impact of using drug-coated balloons (DCBs) in the treatment of coronary artery lesions in patients with multivessel coronary artery disease (MVD), as opposed to the default strategy of using only drug-eluting stents (DES). The investigators aim to assess changes in clinical practice towards a hybrid treatment strategy (DES and DCB) and its effects on clinical outcomes.

03

Conditions studied

  • Coronary Artery Disease
  • Multi Vessel Coronary Artery Disease

Keywords

  • Coronary artery disease
  • Multivessel coronary artery disease
  • Percutaneous coronary intervention
  • Drug-coated balloon
  • Drug-eluting stent
04

Who can participate

Ages eligible
19 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with multivessel coronary artery disease who undergo coronary intervention

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 19 or older
  2. Multivessel coronary artery disease patients requiring coronary intervention

    • Stenosis of 2 or more major coronary arteries or major coronary artery branches (Vessel size ≥2.5mm) with diameter stenosis ≥50% or fractional flow reserve ≤0.80 requiring repeat revascularization
    • Having stenotic lesions requiring revascularization with a vessel size of 2.5mm to 3.0mm
  3. Capable of understanding the risks and benefits of participating in the study and providing

Exclusion criteria

Exclusion Criteria:

  1. Incapable of voluntarily providing
  2. Allergy or to aspirin, P2Y12 inhibitors, or components of drug-eluting stents
  3. Cardiogenic shock or cardiac arrest patients
  4. Patients with severe left ventricular systolic dysfunction ( \<30%)
  5. Patients for whom coronary artery bypass surgery is prioritized over coronary artery intervention
  6. Patients with severe valvular heart disease requiring open heart surgery
  7. Pregnant or lactating women
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • Hybrid strategy

    The patient undergoes percutaneous coronary intervention with drug-coated balloons and drug-eluting stents or drug-coated balloons only in the coronary artery lesion.

    Device: drug-coated balloon · Device: drug-eluting stent

  • DES only

    The patient undergoes percutaneous coronary intervention with drug-eluting stents only in the coronary artery lesion.

    Device: drug-eluting stent

Interventions

  • Devicedrug-coated balloon

    For the procedure, the drug-coated balloon (Agent®, Boston Scientific, USA) that can be used for both de-novo coronary lesions and in-stent restenosis lesions is used.

  • Devicedrug-eluting stent

    When using drug-eluting stents, the latest 2nd generation drug-eluting stent (Synergy®, Boston Scientific, USA) should be used in accordance with the latest guidelines.

06

What researchers measure

Primary outcomes

  1. The reclassification rate of the treatment strategy

    The reclassification rate according to the change in treatment approach from the default strategy of using only drug-eluting stents (DES-only) to the hybrid strategy of using both drug-coated balloons and drug-eluting stents in the treatment of multivessel coronary artery disease.

    Time frame: At the time of procedure

Secondary outcomes

  1. Rate of change in treatment pattern from drug-eluting stents to drug-coated balloons in target vessel therapy

    Rate of change in treatment pattern from drug-eluting stents to drug-coated balloons in target vessel therapy

    Time frame: At the time of procedure

  2. Rate of change in treatment pattern from drug-eluting stents to drug-coated balloons in target lesion therapy

    Rate of change in treatment pattern from drug-eluting stents to drug-coated balloons in target lesion therapy

    Time frame: At the time of procedure

  3. Cardiovascular death

    Cardiovascular death

    Time frame: 1 year

  4. All-cause death

    All-cause death

    Time frame: 1 year

  5. Non-fatal myocardial infarction (MI)

    Non-fatal myocardial infarction (MI)

    Time frame: 1 year

  6. Target vessel MI excluding periprocedural MI

    Target vessel MI excluding periprocedural MI

    Time frame: 1 year

  7. Target vessel MI including periprocedural MI

    Target vessel MI including periprocedural MI

    Time frame: 1 year

  8. Clinically indicated target lesion revascularization

    Clinically indicated target lesion revascularization

    Time frame: 1 year

  9. Clinically indicated target vessel revascularization

    Clinically indicated target vessel revascularization

    Time frame: 1 year

  10. Any revascularization

    Any revascularization

    Time frame: 1 year

  11. Vessel or stent thrombosis, definite or probable by Academic Research Consortium (ARC) definition

    Vessel or stent thrombosis, definite or probable by Academic Research Consortium (ARC) definition

    Time frame: 1 year

  12. Cardiovascular death or target vessel MI

    Cardiovascular death or target vessel MI

    Time frame: 1 year

  13. All-cause death or non-fatal MI

    All-cause death or non-fatal MI

    Time frame: 1 year

  14. Target vessel failure (TVF), including cardiovascular death, target vessel MI, or clinically indicated target vessel revascularization

    Target vessel failure (TVF), including cardiovascular death, target vessel MI, or clinically indicated target vessel revascularization

    Time frame: 1 year

  15. Target lesion failure (TLF), including cardiovascular death, target lesion MI, or clinically indicated target lesion revascularization

    Target lesion failure (TLF), including cardiovascular death, target lesion MI, or clinically indicated target lesion revascularization

    Time frame: 1 year

  16. Cardiovascular death, target vessel MI, or vessel or stent thrombosis

    Cardiovascular death, target vessel MI, or vessel or stent thrombosis

    Time frame: 1 year

  17. All-cause death, non-fatal MI, or clinically indicated target vessel revascularization

    All-cause death, non-fatal MI, or clinically indicated target vessel revascularization

    Time frame: 1 year

  18. Major bleeding events (BARC type 2, 3, or 5)

    Major bleeding events (BARC type 2, 3, or 5)

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Aug 2025, 23 months after the start.

Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 23 months is below that.

Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2023
First posted
Oct 27, 2023
StartActual
Sep 18, 2023
Primary completionEst.
Aug 31, 2025
CompletionEst.
Oct 31, 2026
Last update
Oct 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06104033
Lead sponsor
Bon-Kwon Koo
Collaborators
Seoul National University Hospital, St Vincent's Hospital, Uijeongbu St. Mary Hospital, Gachon University Gil Medical Center, Gangnam Severance Hospital, Kyunghee University Medical Center, Keimyung University Dongsan Medical Center, Inje University Ilsan Paik Hospital, Daegu Catholic University Medical Center, Sejong General Hospital, Seoul National University Bundang Hospital, Soonchunhyang University Hospital, Yeungnam University Hospital, Wonju Severance Christian Hospital, Ulsan University Hospital, Ewha Womans University Mokdong Hospital, Inje University, Chonnam National University Hospital, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University Hosptial, Chung-Ang University College of Medicine, Ulsan Medical Center, Hanyang University Seoul Hospital, Jeju National University Hospital, KangWon National University Hospital, Uijeongbu Eulji Medical Center, Eulji University, Seoul St. Mary's Hospital, Gyeongsang National University Hospital, Severance Hospital, Chosun University Hospital, Kyungpook National University Hospital, Korea University Anam Hospital, Kyung Hee University Hospital at Gangdong, Ajou University School of Medicine
Responsible party
Bon-Kwon Koo (Professor, Seoul National University Hospital) — Sponsor-investigator
First posted
Oct 27, 2023
Start date
Sep 18, 2023
Primary completion
Aug 31, 2025 (estimated)
Completion
Oct 31, 2026 (estimated)
Last update
Oct 27, 2023

Study contacts

Bon-Kwon Koo, MD, PhD
Contact
bkkoo@snu.ac.kr
+82-2-2072-2062
Bon-Kwon Koo, MD, PhD
study chair · +82-2-2072-2062

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion